(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
4 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
-0.45% ¥ 1 535.00
Live Chart Being Loaded With Signals
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 196 700 |
Średni wolumen | 305 953 |
Kapitalizacja rynkowa | 63.91B |
EPS | ¥0 ( 2024-02-01 ) |
Następna data zysków | ( ¥12.99 ) 2024-05-08 |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 11.61 |
ATR14 | ¥0.938 (0.06%) |
Wolumen Korelacja
Shin Nippon Biomedical Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Shin Nippon Biomedical Korelacja - Waluta/Towar
Shin Nippon Biomedical Finanse
Annual | 2022 |
Przychody: | ¥25.09B |
Zysk brutto: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Przychody: | ¥25.09B |
Zysk brutto: | ¥13.05B (52.00 %) |
EPS: | ¥145.57 |
FY | 2022 |
Przychody: | ¥17.75B |
Zysk brutto: | ¥9.69B (54.58 %) |
EPS: | ¥171.20 |
FY | 2021 |
Przychody: | ¥15.11B |
Zysk brutto: | ¥7.55B (49.99 %) |
EPS: | ¥87.95 |
Financial Reports:
No articles found.
Shin Nippon Biomedical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥20.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥0.500 | 2004-03-26 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | ¥99.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.65 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.81 | |
Div. Directional Score | 7.68 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3681.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2975.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
1827.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9832.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8345.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7730.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
6904.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6266.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
4977.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.206 | 1.500 | 5.88 | 8.82 | [0 - 0.5] |
returnOnAssetsTTM | 0.0771 | 1.200 | 7.43 | 8.92 | [0 - 0.3] |
returnOnEquityTTM | 0.192 | 1.500 | 8.98 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.496 | 0.800 | 7.52 | 6.02 | [1 - 3] |
quickRatioTTM | 0.835 | 0.800 | 9.80 | 7.84 | [0.8 - 2.5] |
cashRatioTTM | 0.571 | 1.500 | 7.94 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.374 | -1.500 | 3.77 | -5.65 | [0 - 0.6] |
interestCoverageTTM | 30.41 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.884 | -1.500 | 6.46 | -9.69 | [0 - 2.5] |
grossProfitMarginTTM | 0.522 | 1.000 | 4.63 | 4.63 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.150 | 1.000 | 9.01 | 9.01 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.134 | 1.000 | -0.368 | -0.368 | [0.2 - 2] |
assetTurnoverTTM | 0.374 | 0.800 | -0.839 | -0.671 | [0.5 - 2] |
Total Score | 10.55 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.61 | 1.000 | 8.93 | 0 | [1 - 100] |
returnOnEquityTTM | 0.192 | 2.50 | 9.34 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.26 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 85.79 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.775 | 1.500 | -8.50 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.134 | 1.000 | 9.16 | 0 | [0.1 - 0.5] |
Total Score | 4.81 |
Shin Nippon Biomedical
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej